Special Digital Issue

KKR's $1 Trillion Gamble

A Wall Street legend gets a radical makeover, and more from Coins2Day

Business news doesn't take a summer break. In the past six weeks our award-winning editorial staff has written must-read stories about private equity, crypto iniquity, misbehaving poultry royalty, and much more.

KKR’s co-CEOs want to reach $1 trillion in assets by 2030. It will require the PE firm to operate very differently than its founders envisioned
Finance

KKR’s co-CEOs want to reach $1 trillion in assets by 2030. It will require the PE firm to operate very differently than its founders envisioned

By
August 27, 2024
Police mugshot of Tyson chief financial officer John R. Tyson
Leadership

The youngest Coins2Day 500 CFO was set up to run his family’s $21 billion chicken empire. His erratic behavior could change that

By
August 6, 2024
Amazon execs Jassy and Bezos - Bezos holds up a fictitious book of "Leadership Principles"
Tech

Jeff Bezos’s famed management rules are slowly unraveling inside Amazon. Can they survive the Andy Jassy era?

By
July 31, 2024
middle-aged man wearing blue t-shirt speaking during an interview
Tech

Inside Iconiq Growth, one of Silicon Valley’s most mysterious venture capital funds that just closed a $5.8B startup war chest

By
July 22, 2024
Portraits of Kanav Kariya and Do Kwon pixelated on a purple background.
Features

A secretive trading firm got itself a crypto arm and a 25-year-old whiz kid to run it. Then came the $40 billion Terra disaster

By
July 11, 2024
A person using Ozempic on November 2, 2023, in Madrid, Spain. Novo Nordisk, the Danish firm that manufactures Ozempic, has reported record quarterly results, up almost 3% on the stock market. The company's revenues rose by 38% to DKK 58.73 billion, some 7.8 billion euros. Ozempic is a diabetic drug that causes a loss of up to 15% of body weight because it acts as an appetite suppressant, a side effect that has made the drug fashionable on social media as a weight loss drug.
Features

Ozempic and Wegovy are marketed as a short-term holy grail for weight loss by some startups. Doctors disagree

By Jessica Mathews and Alena Botros
July 9, 2024

Most Popular